Zymeworks

Zymeworks P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Zymeworks (ZYME) as of Oct 24, 2026 is -51.04. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -15.31 — a change of 233.42% (lower).

P/CF

-51.04

YoY

233.42%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Zymeworks is 2025 -51.04 . P/CF (Price-to-Cash-Flow Ratio) of Zymeworks was 2024 -15.31 . It decreases by 233.42% lower compared to the previous year.

The Zymeworks P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
69.68 USD
Jan 1, 2019
-20.58 USD
Jan 1, 2020
-11.13 USD
Jan 1, 2021
-8.75 USD
Jan 1, 2022
11.69 USD
Jan 1, 2023
-14.24 USD
Jan 1, 2024
-15.31 USD
Jan 1, 2025
-51.04 USD
The Zymeworks P/CF history
YEARP/CFYoY
-51.04+233.42%
-15.31+7.51%
-14.24-221.81%
11.69-233.55%
-8.75-21.33%
-11.13-45.94%
-20.58-129.54%
69.68-99.09%
7,692.10-16,194.06%
-47.79-37.10%
-75.98-68.35%
-240.10—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zymeworks Stock analysis

What does Zymeworks do? Zymeworks, Inc. generates revenue through its clinical-stage biopharmaceutical products and platforms. The company develops biotherapeutics using its Azymetric bispecific platform, which creates antibodies binding multiple targets, and its ZymeLink ADC platform, combining cytotoxins with tumor-targeting antibodies. Lead product ZW25 targets HER2 for cancer treatment, while ZW49 integrates ZW25 design with ZymeLink for enhanced therapy. These products are developed for clinical trials and potential commercialization, with revenue expected from future partnerships or sales once approved. Zymeworks focuses on oncology and immune modulation, leveraging its EFECT platform for immune cell recruitment control. The company’s platforms and product candidates are designed for pharmaceutical partnerships, with potential buyers including biopharmaceutical firms seeking innovative cancer therapies. Revenue streams will emerge from licensing agreements, milestone payments, and future product sales once clinical development progresses. The company’s product pipeline includes ZW25 and ZW49, both targeting HER2-related cancers. ZW25 uses Azymetric technology, while ZW49 incorporates ZymeLink for antibody-drug conjugates. These are developed for potential commercialization, with revenue anticipated from biopharmaceutical partners who license these technologies or products for further development and marketing. Zymeworks is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zymeworks stock

P/CF (Price-to-Cash-Flow Ratio) of Zymeworks is -51.04 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Zymeworks changed from -15.31 to -51.04, representing a 233.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Zymeworks since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Zymeworks with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Zymeworks

All Key Metrics — Zymeworks